News | August 01, 2025
Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
